入排依据:The abstract describes a randomized, phase III, drug-intervention trial in oncology. However, it does not explicitly report any time-to-event efficacy endpoint (OS, PFS, DFS, HR, or Kaplan-Meier results). The deterministic review also flagged a lack of time-to-event signal. Eligibility cannot be confirmed without explicit efficacy outcome data.
摘要
摘要
Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study. The TAILOR study is the first randomized, multicenter, prospective Phase III study evaluating the addition of cetuximab to FOLFOX in a RAS wt Chinese population and thus providing confirmatory data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone.
KM 提取结果
0 个 Figure · 0 个 KM 面板